Logo

Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

Share this
Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

Shots:

  • The approval is based on the data from PK bridging studies and P-III EVOLVE-MS-2 study to evaluate the GI tolerability of Vumerity vs Tecfidera in patients with relapsing-remitting MS
  • In the EVOLVE-MS-2 study, the therapy demonstrated a low rate of overall treatment discontinuation due to GI tolerability (1.6% vs 6%). Additionally, flushing was reported in patients treated with Vumerity & Tecfidera (32.8% & 40.6%), no serious events of flushing or discontinuations were observed
  • Vumerity is oral fumarate & has received the US FDA approval in Oct 2019. The therapy is also approved in Great Britain and Switzerland

/ article Ref: Globe Newswire | ImageBiogen

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions